• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种新型噬菌体裂解素-人类防御素融合蛋白对小鼠感染治疗有效。

A Novel Bacteriophage Lysin-Human Defensin Fusion Protein Is Effective in Treatment of Infection in Mice.

作者信息

Peng Zhong, Wang Shaohui, Gide Mussie, Zhu Duolong, Lamabadu Warnakulasuriya Patabendige Hiran Malinda, Li Chunhui, Cai Jianfeng, Sun Xingmin

机构信息

Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, United States.

State Key Laboratory of Agricultural Microbiology, College of Animal Science and Veterinary Medicine, Huazhong Agricultural University, Wuhan, China.

出版信息

Front Microbiol. 2019 Jan 11;9:3234. doi: 10.3389/fmicb.2018.03234. eCollection 2018.

DOI:10.3389/fmicb.2018.03234
PMID:30687250
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6336692/
Abstract

is the leading cause of worldwide antibiotics-associated diarrhea. In this study, we report the construction and evaluation of a novel bacteriophage lysin-human defensin fusion protein targeting . The fusion protein, designated LHD, is composed of two parts connected by a 3-repeating unit linker "(GGGGS)": the catalytic domain of a lysin protein from a bacteriophage phiC2 (LCD), and the functional domain of a human defensin protein HD. Lytic assays showed that LHD protein had a potent lytic activity against different types of clinical strains, including the epidemic 027, 078, 012, and 087 strains. The minimum inhibitory concentration (MIC) of LHD was 0.78 μg/ml, which was lower than the MIC of the protein LCD (1.56 μg/ml), and the MICs of metronidazole (4 μg/ml) and vancomycin (4 μg/ml). In addition, the LHD protein could lyse strains in different pHs (6.0, 7.0, and 8.0). Evaluation of LHD potency using mouse model of infection (CDI) showed that administration of the LHD protein (twice daily for 7 days) was effective in mitigating the symptoms and reducing the death from CDI. Treatment with LHD also significantly decreased the number of spores and the toxin level in feces from the infected mice. Our data suggest that this novel lysin-human defensin fusion protein has a potential on CDI control.

摘要

是全球抗生素相关性腹泻的主要原因。在本研究中,我们报告了一种新型噬菌体溶菌酶-人防御素融合蛋白靶向……的构建及评估。该融合蛋白命名为LHD,由通过3个重复单元连接子“(GGGGS)”连接的两部分组成:来自噬菌体phiC2的溶菌酶蛋白的催化结构域(LCD)和人防御素蛋白HD的功能结构域。溶菌试验表明,LHD蛋白对不同类型的临床……菌株具有强大的溶菌活性,包括流行的027、078、012和087菌株。LHD的最低抑菌浓度(MIC)为0.78μg/ml,低于蛋白LCD的MIC(1.56μg/ml)以及甲硝唑(4μg/ml)和万古霉素(4μg/ml)的MIC。此外,LHD蛋白可在不同pH值(6.0、7.0和8.0)下裂解……菌株。使用艰难梭菌感染(CDI)小鼠模型评估LHD的效力表明,给予LHD蛋白(每日两次,共7天)可有效减轻症状并降低CDI导致的死亡。用LHD治疗还显著降低了感染小鼠粪便中……芽孢的数量和毒素水平。我们的数据表明,这种新型溶菌酶-人防御素融合蛋白在控制CDI方面具有潜力。

相似文献

1
A Novel Bacteriophage Lysin-Human Defensin Fusion Protein Is Effective in Treatment of Infection in Mice.一种新型噬菌体裂解素-人类防御素融合蛋白对小鼠感染治疗有效。
Front Microbiol. 2019 Jan 11;9:3234. doi: 10.3389/fmicb.2018.03234. eCollection 2018.
2
Antimicrobial Activity of Tannic Acid and Its Protective Effect on Mice against Clostridioides difficile.没食子酸的抗菌活性及其对艰难梭菌感染小鼠的保护作用。
Microbiol Spectr. 2023 Feb 14;11(1):e0261822. doi: 10.1128/spectrum.02618-22. Epub 2022 Dec 20.
3
Assessing the Feasibility of Employing a Combination of a Bacteriophage-Derived Endolysin and Spore Germinants to Treat Relapsing Infection.评估联合使用噬菌体来源的内溶素和芽孢萌发剂治疗复发性感染的可行性。
Microorganisms. 2023 Jun 24;11(7):1651. doi: 10.3390/microorganisms11071651.
4
Bacteriophage endolysins as a potential weapon to combat infection.噬菌体溶菌素作为对抗感染的潜在武器。
Gut Microbes. 2020 Nov 9;12(1):1813533. doi: 10.1080/19490976.2020.1813533.
5
Influence of Binary Toxin Gene Detection and Decreased Susceptibility to Antibiotics among Clostridioides difficile Strains on Disease Severity: a Single-Center Study.艰难梭菌菌株中二元毒素基因检测和抗生素敏感性降低对疾病严重程度的影响:一项单中心研究。
Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0048922. doi: 10.1128/aac.00489-22. Epub 2022 Jul 21.
6
Oral teicoplanin administration suppresses recurrence of Clostridioides difficile infection: Proof of concept.口服替考拉宁可抑制艰难梭菌感染的复发:概念验证。
Anaerobe. 2023 Dec;84:102789. doi: 10.1016/j.anaerobe.2023.102789. Epub 2023 Oct 23.
7
Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models.通过基于体内粪便的感染评估模型阐明非达霉素和万古霉素对艰难梭菌感染的粪便药代动力学/药效学特征。
Clin Microbiol Infect. 2023 May;29(5):616-622. doi: 10.1016/j.cmi.2022.12.015. Epub 2022 Dec 24.
8
CDBN-YGXZ, a Novel Small-Molecule Drug, Shows Efficacy against Clostridioides difficile Infection and Recurrence in Mouse and Hamster Infection Models.CDBN-YGXZ,一种新型小分子药物,在艰难梭菌感染和复发的小鼠和仓鼠感染模型中显示出疗效。
Antimicrob Agents Chemother. 2023 May 17;67(5):e0170422. doi: 10.1128/aac.01704-22. Epub 2023 Apr 13.
9
Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection.非培养方法诊断艰难梭菌感染时代粪便培养中产毒艰难梭菌生长的临床意义。
Microbiol Spectr. 2021 Oct 31;9(2):e0079921. doi: 10.1128/Spectrum.00799-21. Epub 2021 Oct 20.
10
Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials.利用噬菌体传递的 CRISPR-Cas3 抗菌剂靶向艰难梭菌。
mBio. 2020 Mar 10;11(2):e00019-20. doi: 10.1128/mBio.00019-20.

引用本文的文献

1
Enzymatic Regulation of the Gut Microbiota: Mechanisms and Implications for Host Health.肠道微生物群的酶促调节:机制及其对宿主健康的影响
Biomolecules. 2024 Dec 20;14(12):1638. doi: 10.3390/biom14121638.
2
Bacteriophage as a potential biotherapeutics to combat present-day crisis of multi-drug resistant pathogens.噬菌体作为应对当今多重耐药病原体危机的一种潜在生物疗法。
Heliyon. 2024 Sep 5;10(18):e37489. doi: 10.1016/j.heliyon.2024.e37489. eCollection 2024 Sep 30.
3
Role of bacteriophages in shaping gut microbial community.噬菌体在塑造肠道微生物群落中的作用。

本文引用的文献

1
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).临床实践指南:成人和儿童艰难梭菌感染:美国传染病学会(IDSA)和美国医疗保健流行病学学会(SHEA)2017 年更新。
Clin Infect Dis. 2018 Mar 19;66(7):987-994. doi: 10.1093/cid/ciy149.
2
Economic Burden of Clostridium difficile Infection in European Countries.欧洲国家艰难梭菌感染的经济负担。
Adv Exp Med Biol. 2018;1050:1-12. doi: 10.1007/978-3-319-72799-8_1.
3
Antibiotic Resistance and Toxin Production of Isolates from the Hospitalized Patients in a Large Hospital in Florida.
Gut Microbes. 2024 Jan-Dec;16(1):2390720. doi: 10.1080/19490976.2024.2390720. Epub 2024 Aug 21.
4
New treatment approaches for infections: alternatives to antibiotics and fecal microbiota transplantation.感染的新治疗方法:抗生素和粪便微生物群移植的替代品。
Gut Microbes. 2024 Jan-Dec;16(1):2337312. doi: 10.1080/19490976.2024.2337312. Epub 2024 Apr 9.
5
The long and sinuous road to phage-based therapy of infections.通往基于噬菌体的感染治疗方法的漫长而曲折之路。
Front Med (Lausanne). 2023 Aug 23;10:1259427. doi: 10.3389/fmed.2023.1259427. eCollection 2023.
6
Assessing the Feasibility of Employing a Combination of a Bacteriophage-Derived Endolysin and Spore Germinants to Treat Relapsing Infection.评估联合使用噬菌体来源的内溶素和芽孢萌发剂治疗复发性感染的可行性。
Microorganisms. 2023 Jun 24;11(7):1651. doi: 10.3390/microorganisms11071651.
7
Emerging applications of phage therapy and fecal virome transplantation for treatment of Clostridioides difficile infection: challenges and perspectives.噬菌体疗法和粪便病毒组移植在艰难梭菌感染治疗中的新兴应用:挑战与展望
Gut Pathog. 2023 May 9;15(1):21. doi: 10.1186/s13099-023-00550-3.
8
Phage therapy for infection.噬菌体疗法治疗 感染。
Front Immunol. 2022 Oct 28;13:1057892. doi: 10.3389/fimmu.2022.1057892. eCollection 2022.
9
Identification of a broad-spectrum lytic Myoviridae bacteriophage using multidrug resistant Salmonella isolates from pig slaughterhouses as the indicator and its application in combating Salmonella infections.利用来自养猪场的多重耐药性沙门氏菌分离株作为指示物鉴定一种广谱裂解性肌尾噬菌体及其在防治沙门氏菌感染中的应用。
BMC Vet Res. 2022 Jul 12;18(1):270. doi: 10.1186/s12917-022-03372-8.
10
Battling Enteropathogenic Clostridia: Phage Therapy for and .对抗肠道致病性梭菌:针对[具体病症1]和[具体病症2]的噬菌体疗法
Front Microbiol. 2022 Jun 13;13:891790. doi: 10.3389/fmicb.2022.891790. eCollection 2022.
佛罗里达州一家大型医院住院患者分离株的抗生素耐药性与毒素产生情况
Front Microbiol. 2017 Dec 22;8:2584. doi: 10.3389/fmicb.2017.02584. eCollection 2017.
4
Genome characterization of a novel binary toxin-positive strain of and comparison with the epidemic 027 and 078 strains.一株新型二元毒素阳性菌株的基因组特征分析及其与流行的027和078菌株的比较。
Gut Pathog. 2017 Aug 7;9:42. doi: 10.1186/s13099-017-0191-z. eCollection 2017.
5
Clostridium difficile Toxin Biology.艰难梭菌毒素生物学。
Annu Rev Microbiol. 2017 Sep 8;71:281-307. doi: 10.1146/annurev-micro-090816-093458. Epub 2017 Jun 28.
6
Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing.艰难梭菌耐药性的最新进展:耐药机制与药敏试验
J Clin Microbiol. 2017 Jul;55(7):1998-2008. doi: 10.1128/JCM.02250-16. Epub 2017 Apr 12.
7
Clostridium difficile disease: Diagnosis, pathogenesis, and treatment update.艰难梭菌疾病:诊断、发病机制及治疗进展
Surgery. 2017 Aug;162(2):325-348. doi: 10.1016/j.surg.2017.01.018. Epub 2017 Mar 6.
8
The Phage Lysin PlySs2 Decolonizes Streptococcus suis from Murine Intranasal Mucosa.噬菌体裂解酶PlySs2可使小鼠鼻内黏膜中的猪链球菌脱菌。
PLoS One. 2017 Jan 3;12(1):e0169180. doi: 10.1371/journal.pone.0169180. eCollection 2017.
9
Burden of Six Healthcare-Associated Infections on European Population Health: Estimating Incidence-Based Disability-Adjusted Life Years through a Population Prevalence-Based Modelling Study.六种医疗保健相关感染对欧洲人群健康的负担:通过基于人群患病率的建模研究估算基于发病率的伤残调整生命年
PLoS Med. 2016 Oct 18;13(10):e1002150. doi: 10.1371/journal.pmed.1002150. eCollection 2016 Oct.
10
Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Prévot 1938.艰难梭菌重新分类为艰难梭杆菌(霍尔和奥图尔,1935年)普雷沃,1938年。
Anaerobe. 2016 Aug;40:95-9. doi: 10.1016/j.anaerobe.2016.06.008. Epub 2016 Jun 28.